InMed Pharmaceuticals (INM) Retained Earnings (2020 - 2026)

InMed Pharmaceuticals' Retained Earnings history runs 7 years deep, the most recent figure standing at -$124.0 million for Q1 2026.

• On a quarterly basis, Retained Earnings fell 96546.27% year-over-year to -$124.0 million in Q1 2026; TTM through Mar 2026 was -$124.0 million, a 96546.27% decrease from a year earlier, with the FY2025 full-year figure at $128569.0, changed 0.0% from the prior year.
• Retained Earnings fell to -$124.0 million in Q1 2026 per INM's latest filing, from -$121.0 million in the prior quarter.
• Across five years, Retained Earnings topped out at $128569.0 in Q2 2022 and bottomed at -$124.0 million in Q1 2026.
• The 5-year median for Retained Earnings is $128569.0 (2022), against an average of -$45.4 million.
• Across the five-year window, Retained Earnings jumped 100.17% in 2022 and sank 96546.27% in 2026, its largest moves.
• Year by year, Retained Earnings stood at -$99.1 million in 2022, then jumped by 100.13% to $128569.0 in 2023, then sank by 88223.89% to -$113.3 million in 2024, then decreased by 6.79% to -$121.0 million in 2025, then retreated by 2.49% to -$124.0 million in 2026.
• Per Business Quant, the three latest INM Retained Earnings figures stand at -$124.0 million (Q1 2026), -$121.0 million (Q4 2025), and -$119.0 million (Q3 2025).